Table 1.

Patient characteristics in Asian and European data sets

	Asian		European
	Oral (n = 47)	Intravenous (n = 34)	Oral/intravenousa (n = 48)
Gender (male/female)	12/35	9/25	11/37
Age (years)	51 [35–71]	53.5 [31–66]	57.5 [25–71]
Body surface area (m2)	1.57 [1.35–1.87]	1.60 [1.30–1.82]	1.71 [1.35–2.11]
Creatinine clearance (ml/min)	97.9 [63.2–252]	96.1 [52.3–179]	79.6 [35.9–127]

Data are presented as number or median [range]

^aPatients from this reference study [11] were randomized to receive first either 80 mg/m² oral vinorelbine, or 30 mg/m² intravenous vinorelbine in a crossover study design with a 2-week washout period. Hence, all 48 patients from the European data set received both oral and intravenous vinorelbine